innovation louisiana 2014 conference program

November 17 – 18

A life sciences entrepreneurship conference presented by

NewOrleansBioInnovationCenter

4

WelcomeWelcome to Innovation Louisiana 2014, a life sciences entrepreneurship and technology commercialization conference for innovators from across the region. National entrepreneurship, industry, and funding experts will offer essential insights and advice on a range of topics critical to growing new life sciences companies. I hope you find the events this week enriching and inspiring as you consider founding or continue to build a new venture.

The New Orleans BioInnovation Center supports the commercialization of technologies and the growth of emerging companies through educational programming like this conference, direct startup development assistance, and state-of-the-art facilities. This year’s conference has drawn more than 100 innovators from across the region, each directly impacting the growth of our regional economy through the attraction of capital and creation of new jobs. In addition to hosting more than 1,100 attendees at educational events since 2011, the Center has now directly assisted over 70 new startups that have created more than 275 competitive jobs across the state and raised $29 million in funding. These businesses are commercializing novel life science and clean technologies developed right here in Louisiana that hold great promise for addressing a wide range of medical and environmental problems.

We hope this event provides valuable education and networking opportunities and helps you better position your company for future success. Thank you for joining us to help build a sustainable biotech industry in Louisiana that fosters startup formation, job creation, and economic growth throughout the state.

Aaron MiscenichPresident, New Orleans BioInnovation Center

Conference Partners

PAGE 2

The Perkin Fund

Agenda

Monday, November 178:30 am RegistRation opens

9:00 – 9:15 opening RemaRks

9:15 – 10:20 panel: UndeRstanding YoUR maRketThis session will explore how to identify and understand the factors that influence the decisions of customers and strategic partners as they interface with a new technology, a critical need for early-stage technology startups.

Moderator: Shafin KhanDirector of Technology Commercialization, New Orleans BioInnovation CenterSandra Coufal, MDCEO, Sibling CapitalJason Doherty, PhDDirector of Startup Consulting Service, Kenan Institute of Private Enterprise, University of North Carolina at Chapel Hill Randy HubbellChief Commercial Officer, Cardiva Medical Craig KrugmanSenior Vice President of Strategic Development, MDoutlookMichael P. SmithBusiness Advisor, NuPotentialChief Financial and Business Advisor, Catalyst Biosciences

10:30 – 11:30 Panel: GRantS anD non-Dilutive FunDinG SouRCeSGrants and other non-dilutive funding sources offer a significant source of capital to small businesses looking to fund research and other activities to help commercialize technologies without sacrificing ownership stakes in their companies. Entrepreneurs can obtain these funds from various sources; including grants, contracts, and business plan competitions. Panelists will highlight the various methods to find and be competitive for these funding opportunities.

Moderator: victor JohnsonManager, Louisiana Tech Transfer Office, Stennis Space CenterGregory Davenport, PhD Vice President, The Conafay GroupRoy KellerDirector, Louisiana Technology Transfer Office andrea WesserAssociate Director, University of Central Florida Office of Research and Commercialization

11:35 – 12:15 SeMinaR: GettinG YouR DuCKS in a RoW: KeY iSSueS in StRuCtuRinG eaRlY StaGe CoMPanieSThis presentation will discuss entity choices for starting a business, key provisions to include in early stage agreements, and other important factors for entrepreneurs to consider when developing a company and raising capital.

Mark Graffagnini, JDPresident, Graffagnini L.C.

12:15 – 1:15 lunCH Sponsored by IBERIABANK

1:15 – 1:55 SeMinaR: intelleCtual PRoPeRtY FoR BioteCHnoloGYSponsored by Novak Druce Connolly Bove + QuiggThis workshop will provide an overview of both the need for patent protection and the legal process to obtain protection of a biotech startup’s intellectual property. The speakers will also address recent legal decisions in the life sciences and how these will impact commercialization of new technologies.

Brian McKnight, JD, Gregory nelson, JD, and Matt todd, JDPartners, Novak Druce Connolly Bove + Quigg

2:00 – 3:00 Panel: DeveloPinG an aDviSoRY BoaRD An effective advisory board provides informed guidance and serves as a tremendous ally to a startup. This panel will discuss the role of an advisory board, how the board should be structured and organized, and how entrepreneurs can attract knowledgeable and engaged thought leaders to guide their growing company.

Moderator: Ben CappielloChief Scientific Officer, BioceptiveHector alila, PhDPresident and CEO, Esperance PharmaceuticalsJennifer HarttDirector of Investments, Life Sciences, Ben Franklin Technology Partners of SoutheasternPennsylvaniaCraig KrugmanSenior Vice President of Strategic Development, MDoutlook

Sue PrestonCo-President, MiniVaxFounder and Senior Vice President, FPRT Bio

3:05 – 4:05 Panel: FoRMinG StRateGiC PaRtneRSHiPS This panel will examine innovative and systematic approaches to product development, from validation of medical needs directly within the health care delivery system to advanced concept creation. The panelists will also discuss how to identify, appeal to, and engage with strategic partners when developing pharmaceutical and biomedical products.

Moderator: Jason Doherty, PhDDirector of Startup Consulting Service, Kenan Institute of Private Enterprise, University of North Carolina at Chapel Hill Randy HubbellChief Commercial Officer, Cardiva Medical andrea WesserAssociate Director, University of Central Florida Office of Research and Commercialization Michael P. SmithBusiness Advisor, NuPotentialChief Financial and Business Advisor, Catalyst Biosciences

4:15 – 5:00 KeYnote anD q&a: ReCoGnizinG WHat You Don’t KnoW anD BuilDinG a SuCCeSSFul BioteCH StaRtuPDr. Coufal is a co-founder of three successful chemical polymer companies and a CEO of a venture capital firm that invests in late and growth stage companies in life and material sciences. Based on her experiences, Dr. Coufal will discuss the basic strategy for creating a team and systematically putting all of the pieces together to create a biotech startup and successfully pursue funding.

Sandra Coufal, MDCEO, Sibling Capital

Tuesday, November 188:30 am RegistRation opens

9:00 – 10:20 Panel: DeveloPinG a ReSeaRCH anD CliniCal tRial StRateGYThe panelists will review the different regulatory approvals required for biotechnologies, how and when to engage with the U.S. Food and Drug Administration, and other factors to consider to successfully navigate the appropriate regulatory channels. This panel will also discuss how to design pre-clinical trials for an easier transition into the clinical phases.

Moderator: Billy Heim Director of Operations, MiniVaxSandra Coufal, MDCEO, Sibling Capital

Jennifer HarttDirector of Investments, Life Sciences, Ben Franklin Technology Partners of Southeastern PennsylvaniaRhonda Paz, PhDSenior Vice President of Clinical Research Operations, GuideStar Clinical Trials ManagementSue PrestonCo-President, MiniVaxFounder and Senior Vice President, FPRT Bio

10:30 – 11:30 Panel: anGel inveStoRS in liFe SCienCeSSponsored by New Orleans Business AllianceA review of the role of angel investors and the issues entrepreneurs must address to receive external capital from these investors. The panelists will discuss what investors look for in financing a venture opportunity, how to reduce barriers to garnering this funding, and how to effectively navigate the process to increase the likelihood of successfully obtaining investment.

Moderator: abhay PatelDirector of Business Development and Industry, New Orleans Business Alliance Geoff DailyExecutive Director, Lafayette General FoundationMike eckertChairman, NO/LA Angel NetworkRobert tucciBoard of Directors, Houston Angel NetworkClayton WhiteDirector, South Coast Angel FundDirector Corporate Development, Renaissance RX

11:35 – 12:15 SeMinaR: tHe BaSiCS oF BRanDinG YouR BuSineSS anD tRaDeMaRKinG YouR PRoDuCtSLearn to distinguish strong trademarks and how they protect customers’ goodwill in the company’s goods and services. The seminar also will include guidelines on the necessary steps that entrepreneurs can take to decrease their risk of infringing on others’ trademark rights.

Micah J. FincherAssociate, Jones Walker

12:15 – 1:15 lunCHSponsored by IBERIABANK

1:15 – 2:25 Panel: ventuRe CaPital FunDinG FoR liFe SCienCeS CoMMeRCializationSponsored by Louisiana Business Incubation AssociationThe panel will address the differences between venture and angel capital. This also will include discussion on the factors that venture capital investors look for in a life science startup, and the best ways entrepreneurs can approach and engage this group of investors.

Moderator: andrea WesserAssociate Director, University of Central Florida Office of Research and Commercialization

Richard Babb Partner and Chief Financial Officer, Louisiana FundsJennifer HarttDirector of Investments, Life Sciences, Ben Franklin Technology Partners of Southeastern PennsylvaniaDale Pfost, PhDGeneral Partner, Advent Life Scienceslauren-Kristine PryzantAnalyst, Mercury Fund Venture Capital Matt RicePartner, Ballast Point Ventures

2:30 – 3:30 CloSinG KeYnote aDDReSS anD q&a: BuilDinG WitH BioloGYNina Tandon will take us through her journey as a scientist and entrepreneur, as well as on an eye-popping tour of the tantalizing array of inventions already being created with nature’s elemental building block, the cell. Imagine the possibilities: broken bridges that have the ability to self-heal, one-stop body-shops for human body parts that render organ donation obsolete, living looms spinning high-tech fabrics, PETA-friendly porterhouse steaks—smarter, more adaptive technologies that may form our future arsenal as we confront looming challenges. With great enthusiasm, Tandon contends that we’re entering a new technological revolution, one in which we can create smarter technologies by making cells our partners in design—often on our own steam, in collaborative biohacking labs—and she confronts the thorny questions that come with playing with the power of life.

nina tandon, PhDCo-founder, EpiBoneintroduction: Jeffrey Gimble, MD, PhDChief Scientific Officer, LaCell

Please join us at 4:00 pm for the 2014 BioChallenge Pitch Competiton and networking Reception.

4:00 pmWelcome and Overview

4:15 pm

BioChallenge Pitch Presentations

JudgesRichard Babb, Louisiana Funds

Sandra Coufal, MD, Sibling CapitalJennifer Hartt, Ben Franklin Technology Partners of Southeastern Pennsylvania

Lauren-Kristine Pryzant, Mercury Fund Venture Capital Matt Rice, Ballast Point Ventures

Robert Tucci, Houston Angel Network

6:00 pmBioChallenge Winner Announcement and Networking Reception

2014 BioChallenge Pitch Competition

PAGE 8

AxOSIM TEChNOLOgIESAxoSim is a contract research organization

dedicated to improving preclinical pharmaceutical development. Utilizing advanced “nerve-on-a-chip” technology, AxoSim facilitates the

prediction of neurological safety and efficacy early in the drug development pipeline. By providing an alternative to animal testing, pharmaceutical

companies will have access to high content data faster and earlier than currently possible.

CRESCENTIuM Crescentium’s product, the GemView LM, is

designed to provide critical care physicians with a safe, inexpensive method of performing surgical procedures like tracheostomies while eliminating complications inherent in current procedures. The

Gem View LM gives physicians the advantage of continuous visualization of the larynx, trachea

or lungs without obstructing or removing the patient’s airway.

ORA ESTuARIESORA Estuaries grows oyster reefs into living

coastal protection infrastructure. ORA Estuaries uses OysterBreak that takes advantage of the oyster’s inherent nature of clustering to form a

coastal protection structure. The oysters not only form a natural breakwater that helps prevent

shoreline erosion and flooding but also help filter water.

TAxOR DIAgNOSTICSTaxor Diagnostics has a diagnostic test to help doctors and patients personalize breast cancer

chemotherapy treatment decisions by predicting whether a certain chemo will be successful for a patient’s specific type of cancer. By making this prediction, patients can be spared from

ineffective chemotherapy regimens and their side effects and also save valuable treatment.

SpeakershECTOR ALILAPresident and CEO, Esperance Pharmaceuticals, Inc.

Hector has over 25 years of management, drug development and research experience in academia in the pharmaceutical and biotech industries. He held senior management positions in big pharma and biotech companies, and he has managed drug development and participated in fundraising, licensing and M&A, IPO roadshows and drug registration. Prior to Esperance, Hector held senior level positions at Protalex, Cell Pathways (acquired by OSI Pharmaceuticals), GeneMedicine (merged with Megabios to become Valentis) and SmithKline Beecham (now GlaxoSmithKline). Hector holds a PhD degree in physiology and immunology from Cornell University and has published several scientific papers in peer-reviewed journals, received several research awards and honors and holds several issued patents. Hector is also a member of the MediFund Board of Louisiana, a special fund in the state treasury to support the advancement of biosciences and medical centers in Louisiana.

RIChARD BABB Partner, Louisiana Funds

Richard has over 20 years of diverse business, accounting and financial management experience, having been a Manager with Ernst & Young’s Entrepreneurial Services Group handling various venture capital clients, the Chief Financial Officer for Medical Science Partners, a Harvard-affiliated life science venture capital fund, and the NASD Chief Compliance Officer for Apeiron Partners LLC. Richard holds a BS in Business Administration from American International College, and he is an inactive Certified Public Accountant with NASD licenses Series 7, 24, 28 & 63.

BEN CAPPIELLO Chief Scientific Officer, Bioceptive

Ben is the inventor of Bioceptive’s IUD insertion tool and the scientific founder. He devised the initial concept while still a student at Tulane University and brought together the current team to found the company in the months following his graduation. He holds a BSE in Biomedical Engineering from Tulane University and certificates in various aspects of women’s health and contraception. Ben was previously an intern in adult stem cell engineering at Boston Biomedical Research Institute in the laboratory of the renowned researcher, James L. Sherley, MD, PhD.

SANDRA I. COufAL CEO, Sibling Capital LLC

Dr. Coufal is co-founder of the private venture firm, Sibling Capital. Prior to this engagement, Dr. Coufal founded Relypsa’s Scientific Advisory Board and co-founded Ilypsa’s Scientific Advisory Board. For the past 13 years, she has been the Biomedical Advisor for the Genomics Institute of the Novartis Research Foundation and continues in this role. For the past 2 years, Dr. Coufal has been Treasurer of the Managing Board of biotech startup MiniVax, Inc., based in New Orleans. She has also been on the Advisory Board of alternative fuel startup ReactWell, LLC., also based in New Orleans. Most recently, Dr. Coufal has been a Founder of Tricida, Inc., as well as its Interim Chairperson and permanent Member of the Board of Directors. Over the past year, Dr. Coufal has been a major investor in the series A funding for Tricida, Inc., through her co-founding of venture firm Sibling Capital Ventures, LLC. Prior to pursuing a career in biotechnology, Dr. Coufal was the Head of the Division of Internal Medicine at the Torrey Pines site of Scripps Clinic in La Jolla, CA. Concurrently, she served as Associate Faculty in the Division of Internal Medicine for UCSD.

gEOff DAILyExecutive Director, Lafayette General Foundation

Geoff is starting up the Lafayette General Foundation for Lafayette General Health, a six-hospital community-owned health system serving the eight parish region of Acadiana. The Foundation is geared towards raising capital to invest in healthcare innovation. In particular, the Foundation is setting up the Lafayette General Innovation Fund to invest in innovative healthcare startups where the health system can serve as a pilot site, early customer, and angel investor to help bring new products and services to market.

gREgORy J. DAvENPORT Vice President, The Conafay Group

Dr. Gregory Davenport has over 22 years of experience in biomedical research with an excellent track record in securing federal funding, building organizations, and managing scientific programs to achieve each company’s mission and objectives. Throughout his career he has provided value-added business solutions to various clients in the life sciences and biotechnology industries, resulting in several rounds of funding and new business totaling over $350 million.

JASON DOhERTyDirector, Startup Consulting Service, Kenan Institute of Private Enterprise, University of North Carolina at Chapel Hill

Jason has over a decade of life sciences research experience in academic and federal labs and nearly five years of experience in technology commercialization and entrepreneurship. The Startup Consulting Service provides market analysis, IP research, and business strategy support to university researchers and entrepreneurs who are developing early-stage, high-impact technologies

and new business ventures. The program leverages core in-house expertise and multi-disciplinary student teams to provide guidance and technical support to carry new innovations through the commercial path.

MIKE ECKERTChairman, NO/LA Angel Network

Mike is the former CEO of The Weather Channel and Pathfire. He is an active angel investor and limited partner in venture capital funds, and he currently serves on the Board of Directors of the national Angel Capital Association.

MICAh fINChERAssociate, Jones Walker

Micah Fincher is an associate in the firm’s Intellectual Property section within the Business & Commercial Litigation Practice Group. His practice focuses on both protecting his client’s IP rights and defending those accused of infringing others’ intellectual property. Mr. Fincher is also an author for the Trade Secret Insider, a legal blog committed to providing timely legal insights on trade secrets, non-competes, computer fraud, and data theft. Mr. Fincher has experience in handling complex patent, trademark, and copyright cases in both state and federal courts and Section 337 investigations before the International Trade Commission. Mr. Fincher also helps clients protect and maximize the value of their businesses’ intellectual property by advising them on all aspects of patent, trade secret, copyright, trademark, and unfair competition law.

MARK gRAffAgNINIPresident, Graffagnini, L.C.

Mark is an attorney focusing on venture and angel capital financings, mergers and acquisitions and strategic partnerships for growth businesses. Mark’s firm has offices in New Orleans and Palo Alto, where he represents companies and investors in a wide variety of transactions.

JENNIfER hARTT Director of Investments, Life Sciences, Ben Franklin Technology Partners of Southeastern Pennsylvania

Jennifer Hartt is Director of Investments, Life Sciences, for Ben Franklin. Hartt directs all of Ben Franklin’s life sciences investments in companies with technologies ranging from clinical healthcare IT, medical devices and diagnostics to therapeutics. Hartt has invested in over forty companies for Ben Franklin since arriving in 2005. Hartt holds a Master’s in Biology and Bachelor’s degree, with both degrees from the University of Pennsylvania. She has prior experience in lab research, clinical settings, business consulting for small and large companies, technology evaluation and transfer, licensing and equity management. Prior to joining Ben Franklin, Hartt was Associate Director of Business Development and Equity at the University of Pennsylvania.

WILLIAM M. hEIMDirector of Operations, MiniVax, Inc.

William Heim has been the Director of Operations of MiniVax for the past three years and has been engaged in every aspect of the day-to-day operations of a biotech startup. He has been involved in accounting, business development, corporate governance, fundraising, grant administration, legal affairs, licensing, and regulatory strategy. Prior to joining MiniVax, William held an internship position at the New Orleans BioInnovation Center in which he worked with over five biotech startup companies. He holds a MBA from the Freeman School of Business at Tulane University and an MS from Georgia Institute of Technology.

RANDy huBBELLChief Commercial Officer, Cardiva Medical

Randy is currently Chief Commercial Officer for Cardiva Medical, a start-up medical device company focused on delivering technology to reduce the complications associated with vascular access. Randy is designing and implementing the commercial strategy and execution to drive the sales of Cardiva’s vascular closure device product line. Before Cardiva, Randy was with Johnson & Johnson for 13 years in various sales and marketing roles, most recently as VP of Global Strategic Marketing at Ethicon Biosurgery. Before moving to Ethicon, Randy worked in the J&J pharmaceutical sector as the WWVP for Global Strategic Marketing (PGSM) for the pain and cardiovascular therapeutic areas. Prior to J&J PGSM, Randy was Executive Director of Strategic Alliances at Cordis Cardiology. Randy started at Cordis in 2001 as Director of Stent Marketing and had responsibility for the launch of CYPHER in the US market in 2003. In 2000, Randy had responsibility for sales and marketing at Enmed, an Internet start-up with web-based technology for conducting clinical trials. Previously, Randy was in sales and marketing for Vasca, a start-up medical device company, and both Boston Scientific and IBM. Randy received his MBA from Loyola University and his BS from Tulane University.

vIC JOhNSONManager, Louisiana Technology Transfer Office/Stennis Space Center

Vic manages the tech transfer office at NASA Stennis Space Center for the LA Business and Technology Center at LSU. He has nearly 20 years working in technology programs, 14 of these with LSU. Vic previously worked at LED as Director of Policy, Planning and Technology Programs. His experience includes working in all phases of SBIR/STTR grants, technology transfer support to NASA, working with federal labs, grant writing, and state support to small technology businesses.

PAGE 10

ROy KELLERDirector, Louisiana Technology Transfer Office

Roy Keller serves as the associate director of the Louisiana Business and Technology Center, a high-tech small business incubator on the campus of Louisiana State University. He also serves as director of the Louisiana Technology Transfer Office (LTTO). The LTTO operates throughout Louisiana and also has offices at NASA’s John C. Stennis Space Center and the NASA Michoud Assembly Facility in New Orleans.

CRAIg KRugMANSenior Vice President, Strategic Development, MDoutlook

Craig directs client focused strategic solutions for successful entrepreneurial consultancy. Based upon over 30 years of experience in pharmaceutical customer insights, commercialization, communications, education and marketing. Particular expertise in commercialization strategies, advocacy development and engagement. Deeply involved in the utilization of cutting edge approaches to deploying the methodologies and tools of data driven business intelligence. Craig also is a leader in the convergence and integration of data insights via cloud based interactive market research platforms.

BRIAN MCKNIghTPartner, Novak Druce Connolly Bove + Quigg

Brian K. McKnight is part of the firm’s nationally recognized Post Grant Law/Patent Reexamination Practice and Litigation Practices. Mr. McKnight’s practice includes defending patent owners in contentious litigation-driven reexaminations, requesting reexamination on behalf of third party requesters and prosecuting critical reissue projects. Mr. McKnight has also represented many patent applicants in drafting and prosecuting patent applications in the fields of biotechnology, computer software, medical devices, mechanical devices and designs. His practice includes the management and prosecution of an international patent portfolio consisting of several hundred matters, as well as providing counsel to several start ups. Mr. McKnight has a strong interest in early stage companies and enjoys working with entrepreneurs to develop IP protection strategies appropriate for the stage of the venture.

gREgORy NELSONPartner, Novak Druce Connolly Bove + Quigg

Gregory A. Nelson represents clients in all phases of patent, trademark and copyright law, including prosecution, licensing and litigation. Mr. Nelson’s clients include a number of Fortune 100 companies and universities whom he assists in developing patent strategies related to biotechnology, chemistry, materials science, and computer and internet technology. Mr. Nelson has extensive experience in the biosciences area, where he represents a number of universities and a national laboratory in obtaining, evaluating, and licensing patents. Mr. Nelson is also very active in BioFlorida, an independent statewide bioscience organization, serving on the Board of Directors. He also co-chaired BioFlorida’s 2005 and 2006 Annual Conference Steering Committees and is a past chair and member of the Executive Committee of the Enterprise Development Council. Mr. Nelson is a founding member and past chair of the Florida Chapter of the Licensing Executives Society.

ABhAy PATELDirector of Business Development and Industry, New Orleans Business Alliance

Abhay Patel serves as the Director of Business Development and Industry for the New Orleans Business Alliance, where he is responsible for corporate retention, expansion and attraction activities. Prior to NOLABA, Abhay spent most of his professional career working as an investment banker, including seven years with Deutsche Bank in New York. While there, he focused on providing capital markets, mergers and acquisitions advisory services for companies across a number of sectors, including healthcare, telecommunications and transportation. During his career, Abhay helped raise over $30 billion of debt and equity capital and worked on several notable advisory transactions, including Hertz’ acquisition of Dollar Thrifty. Abhay earned his undergraduate degree in Finance from LSU and his JD from the Boston University School of Law.

RhONDA J. PAzSr. Vice President Clinical Research Operations, GuideStar Clinical Trials Management

As Senior Vice President of Clinical Research Operations, Dr. Paz is responsible for

strategizing and implementing compliant and efficient operational units at all GuideStar research sites. She holds a Doctorate of Philosophy in Health Administration, as well as a BA in Business Administration and Management. She has over 25 years leadership experience in clinical research and cancer center administration and is a certified Clinical Research Contract Professional.

DALE PfOSTGeneral Partner, Advent Life Sciences

Dale is the US-based General Partner of London-based Advent Life Sciences, one of the leading venture capital funds in Europe. He has been the CEO of 5 successful biotech companies, 3 of which became publically-traded with valuations over $1 billion. He was the founding CEO of Acuity Pharmaceuticals which merged to form OPKO Health. He was the founding CEO of both Oxford GlycoSciences and Orchid BioSciences, which went public in 1998 and 2000. His first company was acquired by SmithKline Beckman. Dale has raised nearly $300 million in 20 financings and has led the M&A of 9 companies and served on multiple boards of directors of public and private companies. He has a PhD in Physics from Brown University and a BS from UC Santa Barbara.

SuE PRESTONCo-President, MiniVax

Sue has more than 25 years of experience in implementing novel regulatory and quality strategies for timely product approvals. She has directed the strategy for over 20 product approvals while in the biotech industry and expansion of marketing efforts into over 60 countries. Before biotech, she spent a decade at the FDA where she pioneered the approval of the first generation of recombinant proteins. Sue has played many roles in biotech including CEO/President of Arriva Pharma and VP Global Regulatory Affairs at Chiron Corp. where she implemented regulatory strategies for technologies including biologics, biotechnology, vaccines, small molecules, gene therapy, novel delivery systems, blood, plasma, tissues and blood screening.

LAuREN-KRISTINE PRyzANTAnalyst, Mercury Fund Venture Capital

Lauren-Kristine is an analyst at Mercury Fund Venture Capital in Houston, TX. She works with the investment team on deal sourcing, investment diligence, and the support of portfolio companies with their operations. Lauren-Kristine has previously worked at Credit Suisse and various startup companies. She graduated with highest honors in finance from the Kenan-Flagler Business School at UNC Chapel Hill, where she was a Morehead-Cain Scholar. Lauren-Kristine is an active part of the Houston business community and most recently has guest lectured at the Bauer School of Business at the University of Houston.

MATT RICEPartner, Ballast Point Ventures

Prior to joining Ballast Point Ventures, Matt worked in the Strategic Alliances group at the Novartis Institutes for BioMedical Research. He also served as an Analyst in the Health Care Investment Banking Group at Raymond James where he focused primarily on the specialty pharmaceutical, drug distribution and contract research organization sectors. Matt spent two years at Ballast Point Ventures as a Senior Associate prior to attending business school. He graduated from the University of Virginia with a bachelor’s degree in Commerce and from the Harvard Graduate School of Business Administration with an MBA. Matt currently serves on the board of directors at Innocutis, Iconixx, MolecularMD, TissueTech and Y-Prime.

MIChAEL P. SMIThBusiness Advisor, NuPotential

Mr. Smith has served as NuPotential’s and Catalyst Biosciences’ Chief Financial Officer and Chief Business Officer since June 2012. He brings over 15 years experience in the biopharmaceutical industry in executive and management roles in Corporate Development, Strategy, Finance, Commercial and Project Management functions for companies ranging in size from 5,000 to 10. Mr. Smith was most recently at iPierian as Vice President of Business Development. Prior to that, he served as CFO and Head of Business Development for Memory Pharmaceuticals (Nasdaq: MEMY), which was acquired by Roche in 2009, where he was responsible for overseeing all business development, finance, strategic planning, intellectual property and eventually site operation activities. Prior to Memory, Mr. Smith was Vice President of Business Development at QLT, Inc. (Nasdaq: QLTI). Mr. Smith entered the industry with Chiron (Nasdaq: CHIR) which was acquired by Novartis in 2006. Throughout his career, Mr. Smith has managed and led numerous hundred+ million dollar company acquisitions, product licensing transactions and strategic partnerships and financings. Mr. Smith holds a BS from the University of Virginia, as well as an MBA from the University of California, Berkeley.

NINA TANDONCEO and Co-Founder, EpiBone

Tandon is on the cutting edge of science: where sci-fi meets reality. She is the CEO of EpiBone, the country’s first company growing living human bones for skeletal reconstruction. She also writes about the new frontier of biotech: homes, textiles, and videogames made of cells. Profiled in Wired and named one of Fast Company’s Most Creative People in Business, she speaks on the future of healthcare and technology, and biology’s new industrial revolution.

MATT TODDPartner, Novak Druce Connolly Bove + Quigg

Matt Todd serves as the Administrative Partner at Novak Druce and is the Co-Chair of the firm’s New Ventures & Corporate

PAGE 12

Transactions Practice. Mr. Todd counsels clients on all aspects of domestic and international patent, trademark and copyright use, registration, enforcement, and licensing. He has managed the trademark portfolios of major U.S. consumer product manufacturers and has extensive experience in domestic and international trademark selection, clearance, use, protection, registration, enforcement, licensing, and merchandising. Mr. Todd is also an experienced litigator in the field of intellectual property involving patents, trademarks, copyrights, false advertising, unfair competition, and trade secrets.

ROBERT RAyMOND TuCCIBoard of Directors, Houston Angel Network

Rob is an active investor, eight year member, board member, and Life Sciences Chair at the Houston Angel Network. He is a member of the University of Houston’s Cougar Fund, serving as a judge and lecturing in the UH Bauer School of Business. At the $6.5M Texas Halo Fund, Rob serves on the managing Board of Directors and directs investments generally within the biotech, life sciences and energy sectors. He is the founder of Yardley Group, LLC, an active chemical development and export business serving South America. Rob has served as a judge at the Rice University Business Plan Competition, the world’s largest. He is an adviser to the National Space Biomedical Research Institute, and Houston Health Ventures, where he is also a founding member. Rob is on the Board of Directors of Adient Medical. A chemist and Tulane MBA, Rob resides in Houston, TX with his physician wife.

ANDREA WESSERAssociate Director, University of Central Florida Office of Commercialization and Research

Although trained as an engineer, Ms. Wesser’s chief responsibilities have been involved in technology economic development for the Southeastern US, state of Florida and the Central Florida region. She has assisted hundreds of entrepreneurs, research faculty and students over nearly ten years in starting technology companies, pursuing federal funding for R&D and generating revenues. Ms. Wesser also worked for several microtechnology focused start-ups, most notably a National Labs’ spin-out for state of the art batteries, Planar Energy Devices. Most recently, she was appointed Associate Director of Business Development for the smart sensors industry-led manufacturing center, the International Consortium for Advanced Manufacturing Research.

CLAyTON WhITEDirector, Corporate Development, Renaissance RXDirector, South Coast Angel Fund

Clayton has over 25 years experience in legal, finance, budgeting, management and strategic planning for start-up and early-stage companies. His background includes organizational structure, mergers and acquisitions, due diligence, financial management and controls, capital structures, and corporate governance. He has taken companies through the venture capital process and successful exits. Clayton currently serves as Director of Corporate Development at Renaissance RX and Director of the South Coast Angel Fund.

2nd Annual golf Scramble and SocialWednesday, November 19

Join us on Wednesday, November 19 for the New Orleans BioFund Golf Scramble and Social at TPC Louisiana Golf Course. Established to help small businesses in Louisiana more easily access capital in order to grow, the BioFund provides financing to qualifying small businesses and startups in a broad range of industries. This event offers networking opportunities for professionals in the startup, legal, healthcare, banking, and financial industries, and net proceeds will provide informative workshops for regional entrepreneurs.

12:00 pm: Shotgun Start5:00 pm: Dinner and Networking Reception

gOLf SCRAMBLE AND SOCIAL SPONSORS:

www.neworleansbio.com

Global Entrepreneurship Week is a worldwide celebration of the innovators and job creators who launch startups that bring ideas to life, drive economic growth, and expand human welfare. Each November, GEW inspires people everywhere through local, national, and global activities that connect participants to potential partners, mentors, and investors. GEW is a platform for connection and collaboration—engaging all players along the entrepreneurship spectrum in strengthening ecosystems around the world.

NewOrleansBioInnovationCenter